Argen-X - Asset Resilience Ratio
Argen-X (1AE) has an Asset Resilience Ratio of 25.67% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Argen-X for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Argen-X's Asset Resilience Ratio has changed over time. See Argen-X book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Argen-X's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Argen-X worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.84 Billion | 25.67% |
| Total Liquid Assets | €1.84 Billion | 25.67% |
Asset Resilience Insights
- Very High Liquidity: Argen-X maintains exceptional liquid asset reserves at 25.67% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Argen-X Industry Peers by Asset Resilience Ratio
Compare Argen-X's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Argen-X (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Argen-X.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 30.29% | €1.88 Billion ≈ $2.20 Billion |
€6.20 Billion ≈ $7.25 Billion |
+5.39pp |
| 2023-12-31 | 24.90% | €1.13 Billion ≈ $1.32 Billion |
€4.54 Billion ≈ $5.31 Billion |
-19.51pp |
| 2022-12-31 | 44.41% | €1.39 Billion ≈ $1.63 Billion |
€3.13 Billion ≈ $3.66 Billion |
+9.25pp |
| 2021-12-31 | 35.16% | €1.00 Billion ≈ $1.17 Billion |
€2.85 Billion ≈ $3.33 Billion |
+0.95pp |
| 2020-12-31 | 34.20% | €635.36 Million ≈ $742.80 Million |
€1.86 Billion ≈ $2.17 Billion |
-35.88pp |
| 2019-12-31 | 70.08% | €1.00 Billion ≈ $1.17 Billion |
€1.43 Billion ≈ $1.68 Billion |
+21.07pp |
| 2018-12-31 | 49.01% | €283.53 Million ≈ $331.48 Million |
€578.46 Million ≈ $676.28 Million |
+3.48pp |
| 2017-12-31 | 45.54% | €168.91 Million ≈ $197.47 Million |
€370.91 Million ≈ $433.63 Million |
+39.08pp |
| 2016-12-31 | 6.46% | €6.83 Million ≈ $7.99 Million |
€105.77 Million ≈ $123.66 Million |
-- |
About Argen-X
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more